🇺🇸 FDA
Patent

US 8658778

hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes

granted A61KA61K48/0058A61P

Quick answer

US patent 8658778 (hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes) held by The Board of Regents of the University of Texas System expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K48/0058, A61P, A61P35/00, A61P35/02